EyePoint Pharmaceuticals, Inc. (EYPT) News
Filter EYPT News Items
EYPT News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest EYPT News From Around the Web
Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call
EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting
WATERTOWN, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments
- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled…
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 06, 2020View more earnings on EYPTWebcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6Technicals 52-week high: $2.6952-week low: $0.70Price action over last quarter: down 30.08%Company Profile EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthal...
EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., April 29, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
One of the industry’s highly watched neuroscience drugmakers is cutting more than half of its workforce as it works to revive hope for its sophomore drug candidate and weather a drop in sales.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Ph...